Literature DB >> 17198870

Enhanced growth of myelodysplastic colonies in hypoxic conditions.

James Edwin Thompson1, Joseph Patrick Conlon, Xiaowei Yang, Patricia Vanessa Sanchez, Martin Carroll.   

Abstract

OBJECTIVE: To determine the response of bone marrow progenitor cells from patients with myelodysplastic syndromes (MDS) to culture in physiologic oxygen tension.
METHODS: Methylcellulose progenitor assays using both unfractionated bone marrow mononuclear cells (MNCs) and purified CD34(+) progenitors were performed in atmospheric oxygen (18.6% O(2)) or one of two levels of hypoxia (1% and 3% O(2)). Assays were performed using normal donor marrow, MDS patient marrow, acute myelogenous leukemia marrow or peripheral blood blasts, chronic phase chronic myelogenous leukemia (CML) marrow MNCs, and blast crisis CML peripheral blood.
RESULTS: The majority of MDS samples showed decreased colony-forming units (CFU) in 18.6% O(2) compared to normal controls, as expected. However, in either 1% or 3% O(2), 9 of 13 MDS samples demonstrated augmentation of CFUs beyond that observed in normal controls, with 6 of 13 demonstrating a greater than ninefold augmentation. This effect is cell autonomous, as it persisted after purification of CD34(+) progenitor cells. Additionally, the augmented response to physiologic oxygen tension is specific to MDS, as it was not observed in either acute or chronic myelogenous leukemia samples.
CONCLUSION: These results suggest that the reported decrease in MDS CFUs reflects greater sensitivity of MDS progenitors or their progeny to the nonphysiologic oxygen tensions routinely used in vitro, rather than a true decrease in progenitor frequency. Importantly, these experiments for the first time describe an experimental system that can be used to study the growth of primary cells from patients with MDS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17198870      PMCID: PMC3677695          DOI: 10.1016/j.exphem.2006.08.017

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  77 in total

1.  Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh's model.

Authors:  D C Chow; L A Wenning; W M Miller; E T Papoutsakis
Journal:  Biophys J       Date:  2001-08       Impact factor: 4.033

2.  Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models.

Authors:  D C Chow; L A Wenning; W M Miller; E T Papoutsakis
Journal:  Biophys J       Date:  2001-08       Impact factor: 4.033

3.  Apoptosis in bone marrow of myelodysplastic syndrome patients.

Authors:  A D Bogdanović; G M Janković; M D Colović; D P Trpinać; V Z Bumbasirević
Journal:  Blood       Date:  1996-04-01       Impact factor: 22.113

4.  Preleukemia. The hematologic syndrome preceding acute leukemia.

Authors:  M I Saarni; J W Linman
Journal:  Am J Med       Date:  1973-07       Impact factor: 4.965

5.  Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration.

Authors:  C M Peddie; C R Wolf; L I McLellan; A R Collins; D T Bowen
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

6.  The clinical and biologic significance of abnormal lipid profiles in patients with myelodysplastic syndromes.

Authors:  K Allampallam; D Dutt; C Nair; V Shetty; S Mundle; L Lisak; C Andrews; B Ahmed; L Mazzone; F Zorat; R Borok; M Muzammil; A Gundroo; I Ansaarie; A Raza
Journal:  J Hematother Stem Cell Res       Date:  2000-04

7.  Functional characterization of telomerase RNA variants found in patients with hematologic disorders.

Authors:  Hinh Ly; Rodrigo T Calado; Paulette Allard; Gabriela M Baerlocher; Peter M Lansdorp; Neal S Young; Tristram G Parslow
Journal:  Blood       Date:  2004-11-18       Impact factor: 22.113

8.  Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in 'good' versus 'poor' prognosis patients and correlation with apoptosis-related genes.

Authors:  P Tsoplou; A Kouraklis-Symeonidis; E Thanopoulou; P Zikos; V Orphanos; N C Zoumbos
Journal:  Leukemia       Date:  1999-10       Impact factor: 11.528

9.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1.

Authors:  Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner
Journal:  Nat Med       Date:  2004-07-04       Impact factor: 53.440

10.  Multiple enzymatic defects in mitochondria in hematological cells of patients with primary sideroblastic anemia.

Authors:  Y Aoki
Journal:  J Clin Invest       Date:  1980-07       Impact factor: 14.808

View more
  13 in total

1.  Stem cells, phenotypic inversion, and differentiation.

Authors:  Robert W Siggins; Ping Zhang; David Welsh; Nicole J Lecapitaine; Steve Nelson
Journal:  Int J Clin Exp Med       Date:  2008-01-20

Review 2.  Mitophagy in hematopoietic stem cells: the case for exploration.

Authors:  Aashish Joshi; Mondira Kundu
Journal:  Autophagy       Date:  2013-10-11       Impact factor: 16.016

Review 3.  Iron overload in myelodysplastic syndromes (MDS).

Authors:  Norbert Gattermann
Journal:  Int J Hematol       Date:  2017-11-25       Impact factor: 2.490

Review 4.  Hematopoietic Stem Cells: Normal Versus Malignant.

Authors:  Dustin Carroll; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2017-12-20       Impact factor: 8.401

5.  Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.

Authors:  Catherine C Smith; Amy Paguirigan; Grace R Jeschke; Kimberly C Lin; Evan Massi; Theodore Tarver; Chen-Shan Chin; Saurabh Asthana; Adam Olshen; Kevin J Travers; Susana Wang; Mark J Levis; Alexander E Perl; Jerald P Radich; Neil P Shah
Journal:  Blood       Date:  2017-05-10       Impact factor: 22.113

6.  Mito-protective autophagy is impaired in erythroid cells of aged mtDNA-mutator mice.

Authors:  XiuJie Li-Harms; Sandra Milasta; John Lynch; Christopher Wright; Aashish Joshi; Rekha Iyengar; Geoffrey Neale; Xi Wang; Yong-Dong Wang; Tomas A Prolla; James E Thompson; Joseph T Opferman; Douglas R Green; John Schuetz; Mondira Kundu
Journal:  Blood       Date:  2014-11-19       Impact factor: 22.113

7.  Metabolic restriction of cancer cells in vitro causes karyotype contraction--an indicator of cancer promotion?

Authors:  Ying Li; Paul Héroux; Igor Kyrychenko
Journal:  Tumour Biol       Date:  2011-11-17

8.  Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.

Authors:  F Zhao; A Mancuso; T V Bui; X Tong; J J Gruber; C R Swider; P V Sanchez; J J Lum; N Sayed; J V Melo; A E Perl; M Carroll; S W Tuttle; C B Thompson
Journal:  Oncogene       Date:  2010-03-15       Impact factor: 9.867

Review 9.  Biology of the bone marrow microenvironment and myelodysplastic syndromes.

Authors:  Erinn B Rankin; Anupama Narla; Joseph K Park; Shuo Lin; Kathleen M Sakamoto
Journal:  Mol Genet Metab       Date:  2015-07-20       Impact factor: 4.797

10.  Crenolanib is a selective type I pan-FLT3 inhibitor.

Authors:  Catherine Choy Smith; Elisabeth A Lasater; Kimberly C Lin; Qi Wang; Melissa Quino McCreery; Whitney K Stewart; Lauren E Damon; Alexander E Perl; Grace R Jeschke; Mayumi Sugita; Martin Carroll; Scott C Kogan; John Kuriyan; Neil P Shah
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.